^
    22h
    A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=149, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Feb 2028
    Enrollment closed • Trial completion date
    |
    Keytruda (pembrolizumab) • ezabenlimab (BI 754091) • BI 765179
    22h
    ST101-101: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=125, Active, not recruiting, Sapience Therapeutics | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    HR positive • BRAF mutation
    |
    temozolomide • abiraterone acetate • lucicebtide (ST101)
    23h
    Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers (clinicaltrials.gov)
    P4, N=50, Recruiting, Ottawa Hospital Research Institute | Not yet recruiting --> Recruiting
    Enrollment open
    24h
    Dissemination of BREASTChoice AIM1-B (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, UNC Lineberger Comprehensive Cancer Center
    New trial
    1d
    NORDIS: Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    1d
    BCS_MAX: Maximizing Energy and Reducing Fatigue in Breast Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=50, Active, not recruiting, University of Pittsburgh | Recruiting --> Active, not recruiting
    Enrollment closed
    1d
    EVER-132-002: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (clinicaltrials.gov)
    P3, N=331, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
    1d
    Via Shalva: Pilot Observational Study of an Integrative Cure Stay Program (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University Hospital, Basel, Switzerland
    New trial
    1d
    CRYO-1: Cryoablation in Elderly Patients With Early-Stage Breast Cancer. (clinicaltrials.gov)
    P=N/A, N=61, Not yet recruiting, St. Antonius Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    1d
    Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib (clinicaltrials.gov)
    P2, N=39, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Focus V (anlotinib)
    1d
    Genipin, A Gut Microbiota-Derived Metabolite of Xihuang Pill, Suppresses Triple-Negative Breast Cancer Angiogenesis by Inhibiting HIF-1α/HSPG2 Axis. (PubMed, Phytother Res)
    Overall, Genipin, a gut microbiota-activated metabolite and a key component of XHP, suppresses TNBC angiogenesis by targeting the HIF-1α/HSPG2 pathway. These findings provide mechanistic insights into the therapeutic potential of XHP and highlight Genipin as a promising candidate for antiangiogenic therapy in TNBC.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    1d
    Association of 25-hydroxyvitamin D levels and vitamin D receptor gene polymorphisms with breast cancer risk in Bangladeshi women. (PubMed, Sci Rep)
    No variant correlated with 25(OH)D levels. These findings suggest that FokI, BsmI, and low 25(OH)D independently contribute to BrCa risk in Bangladeshi women.
    Journal • BRCA Biomarker
    |
    VDR (Vitamin D Receptor)